Company Description
Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases.
The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.
It is also involved in the development of adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, currently under Phase 2 studies for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis; and niclosamide, an oral small molecule with anti-inflammatory inhibitor therapy, currently under Phase 2 studies for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, as well as immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients.
The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics, Inc. in May 2024.
Entero Therapeutics, Inc. was incorporated in 2014 and is based in Boca Raton, Florida.
| Country | United States |
| Founded | 2014 |
| IPO Date | Oct 11, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | James R. Sapirstein M.B.A., R.Ph. |
Contact Details
Address: 777 Yamato Road, Suite 502 Boca Raton, Florida 33431 United States | |
| Phone | 561-589-7020 |
| Website | firstwavebio.com |
Stock Details
| Ticker Symbol | ENTO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001604191 |
| Employer ID | 46-4993860 |
| SIC Code | 2834 |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 24, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jun 20, 2024 | 8-K | Current Report |
| Jun 17, 2024 | PRER14A | Filing |
| Jun 14, 2024 | 424B3 | Prospectus |
| Jun 10, 2024 | EFFECT | Notice of Effectiveness |
| Jun 5, 2024 | 8-K | Current Report |
| May 31, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| May 30, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 30, 2024 | 8-K/A | [Amend] Current report |
| May 16, 2024 | 8-K | Current Report |